5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | NEUTRAL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 9.16▼ | 9.15▲ | 9.12▲ | 9.70▼ | 12.19▼ |
MA10 | 9.18▼ | 9.12▲ | 9.10▲ | 10.19▼ | 14.46▼ |
MA20 | 9.18▼ | 9.14▲ | 9.36▼ | 12.12▼ | 15.37▼ |
MA50 | 9.12▲ | 9.65▼ | 9.95▼ | 14.75▼ | N/A |
MA100 | 9.13▲ | 10.03▼ | 11.47▼ | 15.04▼ | N/A |
MA200 | 9.43▼ | 11.70▼ | 12.56▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.008▼ | 0.047▲ | 0.029▲ | -0.235▼ | N/A |
RSI | 50.554▲ | 44.245▼ | 38.099▼ | 24.135▼ | 36.297▼ |
STOCH | 32.468 | 54.551 | 36.219 | 6.234▼ | 10.535▼ |
WILL %R | -63.636 | -37.838 | -69.935 | -94.617▼ | -97.291▼ |
CCI | -86.077 | 60.215 | 5.995 | -97.842 | -164.654▼ |
Wednesday, April 24, 2024 05:14 AM
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
|
Thursday, April 18, 2024 03:36 AM
April 18 (Reuters) - Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Savio D'Souza) Sage ...
|
Wednesday, April 17, 2024 02:31 PM
DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 8.94 | 9.31 | 8.82 | 9.15 | 677,291 |
25/04/24 | 9.48 | 9.8065 | 8.98 | 9.06 | 804,136 |
24/04/24 | 10.30 | 10.465 | 9.48 | 9.59 | 598,717 |
23/04/24 | 10.32 | 10.74 | 10.29 | 10.30 | 328,683 |
22/04/24 | 10.28 | 10.70 | 9.98 | 10.41 | 487,138 |
19/04/24 | 10.56 | 10.72 | 9.96 | 10.18 | 784,324 |
18/04/24 | 10.57 | 10.9062 | 10.22 | 10.55 | 404,261 |
17/04/24 | 11.03 | 11.275 | 10.24 | 10.47 | 606,855 |
16/04/24 | 11.15 | 11.646 | 10.90 | 10.96 | 745,132 |
15/04/24 | 11.08 | 12.35 | 10.73 | 11.19 | 1,992,950 |
|
|
||||
|
|
||||
|
|